These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18971540

  • 1. In vivo imaging of renal redox status during azelnidipine treatment.
    Hirayama A, Ueda A, Oteki T, Nagase S, Aoyagi K, Koyama A.
    Hypertens Res; 2008 Aug; 31(8):1643-50. PubMed ID: 18971540
    [Abstract] [Full Text] [Related]

  • 2. In vivo imaging of oxidative stress in ischemia-reperfusion renal injury using electron paramagnetic resonance.
    Hirayama A, Nagase S, Ueda A, Oteki T, Takada K, Obara M, Inoue M, Yoh K, Hirayama K, Koyama A.
    Am J Physiol Renal Physiol; 2005 Mar; 288(3):F597-603. PubMed ID: 15536173
    [Abstract] [Full Text] [Related]

  • 3. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K.
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
    [Abstract] [Full Text] [Related]

  • 4. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
    Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, Deguchi K, Yamashita T, Abe K.
    Brain Res; 2007 Oct 24; 1176():143-50. PubMed ID: 17904110
    [Abstract] [Full Text] [Related]

  • 5. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
    Nakamoto M, Ohya Y, Sakima A, Yamazato M, Takishita S.
    Hypertens Res; 2007 Apr 24; 30(4):359-66. PubMed ID: 17541215
    [Abstract] [Full Text] [Related]

  • 6. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
    Shokoji T, Fujisawa Y, Kiyomoto H, Rahman M, Sun GP, Fan YY, Kimura S, Kohno M, Abe Y, Nishiyama A.
    Hypertens Res; 2005 Dec 24; 28(12):1017-23. PubMed ID: 16671342
    [Abstract] [Full Text] [Related]

  • 7. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y, Hirooka Y, Sagara Y, Sunagawa K.
    Clin Exp Hypertens; 2007 Jan 24; 29(1):13-21. PubMed ID: 17190727
    [Abstract] [Full Text] [Related]

  • 8. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
    Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K, ATTEST Study Group.
    Hypertens Res; 2008 Aug 24; 31(8):1499-508. PubMed ID: 18971523
    [Abstract] [Full Text] [Related]

  • 9. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M.
    J Pharmacol Exp Ther; 2006 Dec 24; 319(3):1081-7. PubMed ID: 16990512
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
    Nakano K, Egashira K, Tada H, Kohjimoto Y, Hirouchi Y, Kitajima S, Endo Y, Li XH, Sunagawa K.
    J Hypertens; 2006 Sep 24; 24(9):1881-9. PubMed ID: 16915039
    [Abstract] [Full Text] [Related]

  • 13. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
    Fujisawa M, Yorikane R, Chiba S, Koike H.
    J Cardiovasc Pharmacol; 2009 Apr 24; 53(4):325-32. PubMed ID: 19295444
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
    Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.
    Am J Med Sci; 2007 Jun 24; 333(6):321-6. PubMed ID: 17570983
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
    Kurobe H, Matsuoka Y, Hirata Y, Sugasawa N, Maxfield MW, Sata M, Kitagawa T.
    J Thorac Cardiovasc Surg; 2013 Dec 24; 146(6):1501-8. PubMed ID: 23535154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.